Publications

Title	Date	PC3I Authors	Journal
Impact of Interobserver Variability in Manual Segmentation of Non-Small Cell Lung Cancer (NSCLC) Applying Low-Rank Radiomic Representation on Computed Tomography	December 10, 2021	PC3I Authors Charu Aggarwal	Cancers
Phase 2 Trial of Consolidation Pembrolizumab After Proton Reirradiation for Thoracic Recurrences of Non-Small Cell Lung Cancer	August 31, 2023	PC3I Authors Michelle Iocolano; Catherine Lai; Charu Aggarwal; Melina Marmarelis	International Journal of Radiation Oncology, Biology, Physics
Platinum Re-Exposure as a Non-Small Cell Lung Cancer (NSCLC) Treatment Strategy in the Age of Immunotherapy	January 30, 2022	PC3I Authors Melina Marmarelis; Ronac Mamtani; Charu Aggarwal	Clinical Lung Cancer
Molecular response assessment using circulating tumor DNA (ctDNA) in advanced solid tumors	October 3, 2023	PC3I Authors Charu Aggarwal; Dylan G. Scholes	British Journal of Cancer
A benchmark for oncologic outcomes and model for lethal recurrence risk after transoral robotic resection of HPV-related oropharyngeal cancers	March 4, 2022	PC3I Authors Charu Aggarwal	Oral Oncology
Patterns of Failure in Metastatic NSCLC Treated With First Line Pembrolizumab and Use of Local Therapy in Patients With Oligoprogression	October 9, 2023	PC3I Authors Michelle Iocolano; Charu Aggarwal; Melina Marmarelis; Christopher A. D’Avella	Clinical Lung Cancer
Plasma Genotyping at the Time of Diagnostic Tissue Biopsy Decreases Time-to-Treatment in Patients With Advanced NSCLC-Results From a Prospective Pilot Study	April 8, 2022	PC3I Authors Charu Aggarwal; Melina Marmarelis; Christopher A. D’Avella; Anil Vachani	JTO Clinical and Research Reports
Patterns of Failure, Low-Volume Relapse, and Subsequent Ablative Management in Locally Advanced Non-Small Cell Lung Cancer Treated With Definitive Chemoradiation and Consolidation Immune Checkpoint Inhibitors	October 22, 2023	PC3I Authors Michelle Iocolano; Charu Aggarwal; Melina Marmarelis	International Journal of Radiation Oncology, Biology, Physics
Phase II Trial of Combination Nab-paclitaxel and Gemcitabine in Non-squamous Non-small Cell Lung Cancer After Progression on Platinum and Pemetrexed	April 8, 2022	PC3I Authors Charu Aggarwal; Melina Marmarelis; Christopher A. D’Avella	Clinical Lung Cancer
The effective radiation dose to immune cells predicts lymphopenia and inferior cancer control in locally advanced NSCLC	November 26, 2023	PC3I Authors Michelle Iocolano; Charu Aggarwal	Radiotherapy and Oncology
Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I/II trial	April 13, 2022	PC3I Authors Charu Aggarwal	Journal for Immunotherapy of Cancer
Concurrent Circulating Tumor DNA and Tissue Genotyping-Ready for Prime Time?	January 22, 2024	PC3I Authors Charu Aggarwal	JAMA Network Open
COAST: An Open-Label, Phase II, Multidrug Platform Study of Durvalumab Alone or in Combination With Oleclumab or Monalizumab in Patients With Unresectable, Stage III Non-Small-Cell Lung Cancer	April 22, 2022	PC3I Authors Charu Aggarwal	Journal of Clinical Oncology
Acute hospitalizations after proton therapy versus intensity-modulated radiotherapy for locally advanced non-small cell lung cancer in the durvalumab era	January 31, 2024	PC3I Authors Michelle Iocolano; Charu Aggarwal	Cancer
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma	May 31, 2022	PC3I Authors Charu Aggarwal	Journal for Immunotherapy of Cancer
Outcomes in patients treated with frontline immune checkpoint inhibition (ICI) for advanced NSCLC with KRAS mutations and STK11/KEAP1 comutations across PD-L1 levels	March 3, 2024	PC3I Authors Charu Aggarwal	Lung Cancer (Amsterdam, Netherlands)
Aumolertinib in EGFR-Mutant Lung Cancer: Will the Promise of Cost Disruption Ease Access?	June 9, 2022	PC3I Authors Charu Aggarwal	Journal of Clinical Oncology
Development of a robust radiomic biomarker of progression-free survival in advanced non-small cell lung cancer patients treated with first-line immunotherapy	June 15, 2022	PC3I Authors Charu Aggarwal	Scientific Reports
Changes in Circulating Tumor DNA Reflect Clinical Benefit Across Multiple Studies of Patients With Non-Small-Cell Lung Cancer Treated With Immune Checkpoint Inhibitors	August 11, 2022	PC3I Authors Charu Aggarwal	JCO Precision Oncology
Prevalence of ARID1A Mutations in Cell-Free Circulating Tumor DNA in a Cohort of 71,301 Patients and Association with Driver Co-Alterations	September 9, 2022	PC3I Authors Charu Aggarwal	Cancers (Basel)